Ironwood Pharmaceuticals, Inc. (IRWD)

Market Cap	712.13M
Revenue (ttm)	378.42M
Net Income (ttm)	-2.46M
Shares Out	160.03M
EPS (ttm)	-0.02
PE Ratio	n/a
Forward PE	13.48
Dividend	n/a
Ex-Dividend Date	n/a

Volume	10,928,261
Open	3.890
Previous Close	3.880
Day's Range	3.780 - 5.130
52-Week Range	3.060 - 15.700
Beta	0.40
Analysts	Buy
Price Target	12.00 (+169.66%)
Earnings Date	Feb 13, 2025

About IRWD

Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries. The company is also developing IW-3300, a GC-C agonist for the tre...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• IPO Date: Feb 3, 2010
• Employees: 267
• Stock Exchange: NASDAQ
• Ticker Symbol: IRWD
• Website: https://www.ironwoodpharma.com

Analyst Forecast

According to 4 analysts, the average rating for IRWD stock is "Buy." The 12-month stock price forecast is $12.0, which is an increase of 169.66% from the latest price.

Price Target

$12.0

(169.66% upside)

Analyst Consensus: Buy